Create a Free Account
or
Create a Free Account
or
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
The global psychedelic drugs market is projected to grow by USD 1.37 billion by 2028, driven by mental health needs and AI adva...
Needham analyst Bernie McTernan maintains Compass (NYSE:COMP) with a Buy and raises the price target from $5 to $6.
Goldman Sachs analyst Michael Ng maintains Compass (NYSE:COMP) with a Buy and raises the price target from $4 to $4.5.
Barclays analyst Matthew Bouley maintains Compass (NYSE:COMP) with a Equal-Weight and raises the price target from $4 to $5.
Mortgage rates decline as investors expect federal funds rate cuts, but mortgage demand remains challenging. Lowest rates since...
US existing home sales declined 5.4% in June 2024, with median sales price reaching a record high. Slow shift to buyer's ma...
Oppenheimer analyst Jason Helfstein maintains Compass (NYSE:COMP) with a Outperform and maintains $6 price target.
